Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Medtronic plcMDT · Entity 2888 | EVP & Group President Diabetes | September 10, 2019 | September 12, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Medtronic plc
Report date September 10, 2019 · Filed September 12, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 30,761 |
Ending reported balance
After 2019-09-10 transaction · row 17
17 source rows · reconciled sequenceRow 1 · 2019-09-10 · Sale · Disposed 10,000 · Balance 30,761 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $107.00 to $107.39, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Row 2 · 2019-09-10 · Exercise / conversion · Acquired 10,257 · Balance 41,018 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Row 3 · 2019-09-10 · Sale · Disposed 10,257 · Balance 30,761 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $107.10 to $107.43, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Row 4 · 2019-09-10 · Exercise / conversion · Acquired 321 · Balance 31,082 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Row 5 · 2019-09-10 · Sale · Disposed 321 · Balance 30,761 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Row 6 · 2019-09-10 · Exercise / conversion · Acquired 27,254 · Balance 58,015 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Row 7 · 2019-09-10 · Sale · Disposed 27,254 · Balance 30,761 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $107.07 to $107.47, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Row 8 · 2019-09-10 · Exercise / conversion · Acquired 852 · Balance 31,613 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Row 9 · 2019-09-10 · Sale · Disposed 852 · Balance 30,761 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Row 10 · 2019-09-10 · Exercise / conversion · Acquired 19,054 · Balance 49,815 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Row 11 · 2019-09-10 · Sale · Disposed 19,054 · Balance 30,761 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $107.28 to $107.58, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Row 12 · 2019-09-10 · Exercise / conversion · Acquired 595 · Balance 31,356 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Row 13 · 2019-09-10 · Sale · Disposed 595 · Balance 30,761 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Row 14 · 2019-09-10 · Exercise / conversion · Acquired 14,121 · Balance 44,882 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Row 15 · 2019-09-10 · Sale · Disposed 14,121 · Balance 30,761 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F6: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $107.36 to $107.48, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Row 16 · 2019-09-10 · Exercise / conversion · Acquired 423 · Balance 31,184 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Row 17 · 2019-09-10 · Sale · Disposed 423 · Balance 30,761 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $78.00 · Expires 2025-08-03 | Direct | 321 |
Reported balance
After 2019-09-10 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2019-09-10 · Exercise / conversion · Disposed 10,257 · Balance 321 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F7: These options to purchase ordinary shares of New Medtronic for $62.76 per share, which were unvested at the effective time of the Merger, were received in the Merger and represent the conversion of an equal number of Medtronic common stock shares for $62.76 per share. The New Medtronic stock option has the same terms and conditions as the original Medtronic stock option. These options became exercisable in four equal annual installments beginning on July 28, 2015, which was the first anniversary of the grant. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $78.00 · Expires 2025-08-03 | Direct | 0 |
Reported balance
After 2019-09-10 transaction · row 19
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 19 · 2019-09-10 · Exercise / conversion · Disposed 321 · Balance 0 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F7: These options to purchase ordinary shares of New Medtronic for $62.76 per share, which were unvested at the effective time of the Merger, were received in the Merger and represent the conversion of an equal number of Medtronic common stock shares for $62.76 per share. The New Medtronic stock option has the same terms and conditions as the original Medtronic stock option. These options became exercisable in four equal annual installments beginning on July 28, 2015, which was the first anniversary of the grant. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $88.06 · Expires 2026-08-01 | Direct | 9,085 |
Reported balance
After 2019-09-10 transaction · row 20
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 20 · 2019-09-10 · Exercise / conversion · Disposed 27,254 · Balance 9,085 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $88.06 · Expires 2026-08-01 | Direct | 284 |
Reported balance
After 2019-09-10 transaction · row 21
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 21 · 2019-09-10 · Exercise / conversion · Disposed 852 · Balance 284 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $83.97 · Expires 2027-07-31 | Direct | 19,055 |
Reported balance
After 2019-09-10 transaction · row 22
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 22 · 2019-09-10 · Exercise / conversion · Disposed 19,054 · Balance 19,055 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $83.97 · Expires 2027-07-31 | Direct | 596 |
Reported balance
After 2019-09-10 transaction · row 23
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 23 · 2019-09-10 · Exercise / conversion · Disposed 595 · Balance 596 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $89.08 · Expires 2028-07-30 | Direct | 42,364 |
Reported balance
After 2019-09-10 transaction · row 24
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 24 · 2019-09-10 · Exercise / conversion · Disposed 14,121 · Balance 42,364 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $89.08 · Expires 2028-07-30 | Direct | 1,272 |
Reported balance
After 2019-09-10 transaction · row 25
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 25 · 2019-09-10 · Exercise / conversion · Disposed 423 · Balance 1,272 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $107.00 to $107.39, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $107.10 to $107.43, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $107.07 to $107.47, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F5: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $107.28 to $107.58, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F6: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $107.36 to $107.48, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F7: These options to purchase ordinary shares of New Medtronic for $62.76 per share, which were unvested at the effective time of the Merger, were received in the Merger and represent the conversion of an equal number of Medtronic common stock shares for $62.76 per share. The New Medtronic stock option has the same terms and conditions as the original Medtronic stock option. These options became exercisable in four equal annual installments beginning on July 28, 2015, which was the first anniversary of the grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 10, 2019 Filed Sep 12, 2019 17:55 UTC | Medtronic plc MDT · Entity 2888 | Exercise / conversionStock Option (Right to Buy) · Derivative | 423 | $0.00 Strike: $89.08 | $0.00 |
DisclosureSEC source: 0001127602-19-028265 · form4.xml · derivative · entry 25 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,272 Underlying: Ordinary Shares · 423 shares Expires 2028-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 17:55 UTC | Medtronic plc MDT · Entity 2888 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,121 | $0.00 Strike: $89.08 | $0.00 |
DisclosureSEC source: 0001127602-19-028265 · form4.xml · derivative · entry 24 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,364 Underlying: Ordinary Shares · 14,121 shares Expires 2028-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 17:55 UTC | Medtronic plc MDT · Entity 2888 | Exercise / conversionStock Option (Right to Buy) · Derivative | 595 | $0.00 Strike: $83.97 | $0.00 |
DisclosureSEC source: 0001127602-19-028265 · form4.xml · derivative · entry 23 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 596 Underlying: Ordinary Shares · 595 shares Expires 2027-07-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 17:55 UTC | Medtronic plc MDT · Entity 2888 | Exercise / conversionStock Option (Right to Buy) · Derivative | 19,054 | $0.00 Strike: $83.97 | $0.00 |
DisclosureSEC source: 0001127602-19-028265 · form4.xml · derivative · entry 22 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,055 Underlying: Ordinary Shares · 19,054 shares Expires 2027-07-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 17:55 UTC | Medtronic plc MDT · Entity 2888 | Exercise / conversionStock Option (Right to Buy) · Derivative | 852 | $0.00 Strike: $88.06 | $0.00 |
DisclosureSEC source: 0001127602-19-028265 · form4.xml · derivative · entry 21 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284 Underlying: Ordinary Shares · 852 shares Expires 2026-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 17:55 UTC | Medtronic plc MDT · Entity 2888 | Exercise / conversionStock Option (Right to Buy) · Derivative | 27,254 | $0.00 Strike: $88.06 | $0.00 |
DisclosureSEC source: 0001127602-19-028265 · form4.xml · derivative · entry 20 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,085 Underlying: Ordinary Shares · 27,254 shares Expires 2026-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 17:55 UTC | Medtronic plc MDT · Entity 2888 | Exercise / conversionStock Option (Right to Buy) · Derivative | 321 | $0.00 Strike: $78.00 | $0.00 |
DisclosureSEC source: 0001127602-19-028265 · form4.xml · derivative · entry 19 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 321 shares Expires 2025-08-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F7 · derivative.exercise_date: These options to purchase ordinary shares of New Medtronic for $62.76 per share, which were unvested at the effective time of the Merger, were received in the Merger and represent the conversion of an equal number of Medtronic common stock shares for $62.76 per share. The New Medtronic stock option has the same terms and conditions as the original Medtronic stock option. These options became exercisable in four equal annual installments beginning on July 28, 2015, which was the first anniversary of the grant. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 17:55 UTC | Medtronic plc MDT · Entity 2888 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,257 | $0.00 Strike: $78.00 | $0.00 |
DisclosureSEC source: 0001127602-19-028265 · form4.xml · derivative · entry 18 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321 Underlying: Ordinary Shares · 10,257 shares Expires 2025-08-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F7 · derivative.exercise_date: These options to purchase ordinary shares of New Medtronic for $62.76 per share, which were unvested at the effective time of the Merger, were received in the Merger and represent the conversion of an equal number of Medtronic common stock shares for $62.76 per share. The New Medtronic stock option has the same terms and conditions as the original Medtronic stock option. These options became exercisable in four equal annual installments beginning on July 28, 2015, which was the first anniversary of the grant. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 17:55 UTC | Medtronic plc MDT · Entity 2888 | SaleOrdinary Shares | 423 | $107.22 | $45,354.06 |
DisclosureSEC source: 0001127602-19-028265 · form4.xml · nonDerivative · entry 17 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,761 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 17:55 UTC | Medtronic plc MDT · Entity 2888 | Exercise / conversionOrdinary Shares | 423 | $89.08 | $37,680.84 |
DisclosureSEC source: 0001127602-19-028265 · form4.xml · nonDerivative · entry 16 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,184 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 17:55 UTC | Medtronic plc MDT · Entity 2888 | SaleOrdinary Shares | 14,121 | $107.41 | $1,516,764.85 |
DisclosureSEC source: 0001127602-19-028265 · form4.xml · nonDerivative · entry 15 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,761 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $107.36 to $107.48, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 17:55 UTC | Medtronic plc MDT · Entity 2888 | Exercise / conversionOrdinary Shares | 14,121 | $89.08 | $1,257,898.68 |
DisclosureSEC source: 0001127602-19-028265 · form4.xml · nonDerivative · entry 14 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,882 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 17:55 UTC | Medtronic plc MDT · Entity 2888 | SaleOrdinary Shares | 595 | $107.22 | $63,795.90 |
DisclosureSEC source: 0001127602-19-028265 · form4.xml · nonDerivative · entry 13 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,761 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 17:55 UTC | Medtronic plc MDT · Entity 2888 | Exercise / conversionOrdinary Shares | 595 | $83.97 | $49,962.15 |
DisclosureSEC source: 0001127602-19-028265 · form4.xml · nonDerivative · entry 12 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,356 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 17:55 UTC | Medtronic plc MDT · Entity 2888 | SaleOrdinary Shares | 19,054 | $107.41 | $2,046,666.36 |
DisclosureSEC source: 0001127602-19-028265 · form4.xml · nonDerivative · entry 11 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,761 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $107.28 to $107.58, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 17:55 UTC | Medtronic plc MDT · Entity 2888 | Exercise / conversionOrdinary Shares | 19,054 | $83.97 | $1,599,964.38 |
DisclosureSEC source: 0001127602-19-028265 · form4.xml · nonDerivative · entry 10 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,815 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 17:55 UTC | Medtronic plc MDT · Entity 2888 | SaleOrdinary Shares | 852 | $107.22 | $91,351.44 |
DisclosureSEC source: 0001127602-19-028265 · form4.xml · nonDerivative · entry 9 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,761 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 17:55 UTC | Medtronic plc MDT · Entity 2888 | Exercise / conversionOrdinary Shares | 852 | $88.06 | $75,027.12 |
DisclosureSEC source: 0001127602-19-028265 · form4.xml · nonDerivative · entry 8 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,613 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 17:55 UTC | Medtronic plc MDT · Entity 2888 | SaleOrdinary Shares | 27,254 | $107.28 | $2,923,863.63 |
DisclosureSEC source: 0001127602-19-028265 · form4.xml · nonDerivative · entry 7 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,761 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $107.07 to $107.47, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 17:55 UTC | Medtronic plc MDT · Entity 2888 | Exercise / conversionOrdinary Shares | 27,254 | $88.06 | $2,399,987.24 |
DisclosureSEC source: 0001127602-19-028265 · form4.xml · nonDerivative · entry 6 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,015 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 17:55 UTC | Medtronic plc MDT · Entity 2888 | SaleOrdinary Shares | 321 | $107.22 | $34,417.62 |
DisclosureSEC source: 0001127602-19-028265 · form4.xml · nonDerivative · entry 5 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,761 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 17:55 UTC | Medtronic plc MDT · Entity 2888 | Exercise / conversionOrdinary Shares | 321 | $78.00 | $25,038.00 |
DisclosureSEC source: 0001127602-19-028265 · form4.xml · nonDerivative · entry 4 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,082 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 17:55 UTC | Medtronic plc MDT · Entity 2888 | SaleOrdinary Shares | 10,257 | $107.31 | $1,100,647.90 |
DisclosureSEC source: 0001127602-19-028265 · form4.xml · nonDerivative · entry 3 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,761 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $107.10 to $107.43, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 17:55 UTC | Medtronic plc MDT · Entity 2888 | Exercise / conversionOrdinary Shares | 10,257 | $78.00 | $800,046.00 |
DisclosureSEC source: 0001127602-19-028265 · form4.xml · nonDerivative · entry 2 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 17:55 UTC | Medtronic plc MDT · Entity 2888 | SaleOrdinary Shares | 10,000 | $107.09 | $1,070,850.00 |
DisclosureSEC source: 0001127602-19-028265 · form4.xml · nonDerivative · entry 1 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,761 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $107.00 to $107.39, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 01, 2019 Filed Aug 2, 2019 18:13 UTC | Medtronic plc MDT · Entity 2888 | Tax withholdingOrdinary Shares | 5,703 | $102.37 | $583,816.11 |
DisclosureSEC source: 0001127602-19-025930 · form4.xml · nonDerivative · entry 2 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,761 Read SEC document |
| August 01, 2019 Filed Aug 2, 2019 18:13 UTC | Medtronic plc MDT · Entity 2888 | Tax withholdingOrdinary Shares | 4,562 | $102.37 | $467,011.94 |
DisclosureSEC source: 0001127602-19-025930 · form4.xml · nonDerivative · entry 1 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,464 Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 17:50 UTC | Medtronic plc MDT · Entity 2888 | GrantStock Option (Right to Buy) · Derivative | 1,615 | $0.00 Strike: $103.26 | $0.00 |
DisclosureSEC source: 0001127602-19-025553 · form4.xml · derivative · entry 3 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,615 Underlying: Ordinary Shares · 1,615 shares Expires 2029-07-29 F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 17:50 UTC | Medtronic plc MDT · Entity 2888 | GrantStock Option (Right to Buy) · Derivative | 53,829 | $0.00 Strike: $103.26 | $0.00 |
DisclosureSEC source: 0001127602-19-025553 · form4.xml · derivative · entry 2 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,829 Underlying: Ordinary Shares · 53,829 shares Expires 2029-07-29 F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 17:50 UTC | Medtronic plc MDT · Entity 2888 | GrantOrdinary Shares | 8,071 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-025553 · form4.xml · nonDerivative · entry 1 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,026 F1 · kind: The restrictions on these restricted stock units shall lapse 100% on the third anniversary of the Grant Date if the Company's cumulative non-GAAP diluted earnings per share ("EPS") growth during the 36-month period ending on the last day of the Company's fiscal year 2022 equals or exceeds a 3% cumulative compound annual growth rate, as determined by the Compensation Committee. F2 · balance_after: This balance increased by 282 shares due to exempt transactions such as dividend reinvestment and employee stock purchase plan. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 16:51 UTC | Medtronic plc MDT · Entity 2888 | Exercise / conversionStock Option (Right to Buy) · Derivative | 31,731 | $0.00 Strike: $78.00 | $0.00 |
DisclosureSEC source: 0001127602-19-021658 · form4.xml · derivative · entry 4 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,578 Underlying: Ordinary Shares · 31,731 shares Expires 2025-08-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · derivative.exercise_date: These options to purchase ordinary shares of New Medtronic for $62.76 per share, which were unvested at the effective time of the Merger, were received in the Merger and represent the conversion of an equal number of Medtronic common stock shares for $62.76 per share. The New Medtronic stock option has the same terms and conditions as the original Medtronic stock option. These options became exercisable in four equal annual installments beginning on July 28, 2015, which was the first anniversary of the grant. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 16:51 UTC | Medtronic plc MDT · Entity 2888 | SaleOrdinary Shares | 20,933 | $97.49 | $2,040,758.17 |
DisclosureSEC source: 0001127602-19-021658 · form4.xml · nonDerivative · entry 3 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,673 F1 · kind: The exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $97.23 to $97.95, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F4 · balance_after: This balance increased by 959 shares due to exempt transactions such as dividend reinvestment and Employee Stock Purchase Plan. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 16:51 UTC | Medtronic plc MDT · Entity 2888 | SaleOrdinary Shares | 31,731 | $97.49 | $3,093,455.19 |
DisclosureSEC source: 0001127602-19-021658 · form4.xml · nonDerivative · entry 2 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,606 F1 · kind: The exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $97.22 to $97.96, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 16:51 UTC | Medtronic plc MDT · Entity 2888 | Exercise / conversionOrdinary Shares | 31,731 | $78.00 | $2,475,018.00 |
DisclosureSEC source: 0001127602-19-021658 · form4.xml · nonDerivative · entry 1 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,337 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 31, 2018 Filed Sep 5, 2018 16:33 UTC | Medtronic plc MDT · Entity 2888 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,324 | $0.00 Strike: $62.76 | $0.00 |
DisclosureSEC source: 0001127602-18-026803 · form4.xml · derivative · entry 7 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 18,324 shares Expires 2024-07-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options to purchase ordinary shares of New Medtronic for $62.76 per share, which were unvested at the effective time of the Merger, were received in the Merger and represent the conversion of an equal number of Medtronic common stock shares for $62.76 per share. The New Medtronic stock option has the same terms and conditions as the original Medtronic stock option. These options became exercisable in four equal annual installments beginning on July 28, 2015, which was the first anniversary of the grant. Read SEC document |
| August 31, 2018 Filed Sep 5, 2018 16:33 UTC | Medtronic plc MDT · Entity 2888 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,436 | $0.00 Strike: $62.76 | $0.00 |
DisclosureSEC source: 0001127602-18-026803 · form4.xml · derivative · entry 6 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 7,436 shares Expires 2024-07-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options to purchase ordinary shares of New Medtronic for $62.76 per share, which were unvested at the effective time of the Merger, were received in the Merger and represent the conversion of an equal number of Medtronic common stock shares for $62.76 per share. The New Medtronic stock option has the same terms and conditions as the original Medtronic stock option. These options became exercisable in four equal annual installments beginning on July 28, 2015, which was the first anniversary of the grant. Read SEC document |
| August 31, 2018 Filed Sep 5, 2018 16:33 UTC | Medtronic plc MDT · Entity 2888 | Exercise / conversionStock Option (Right to Buy) · Derivative | 399 | $0.00 Strike: $62.76 | $0.00 |
DisclosureSEC source: 0001127602-18-026803 · form4.xml · derivative · entry 5 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 399 shares Expires 2024-07-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options to purchase ordinary shares of New Medtronic for $62.76 per share, which were unvested at the effective time of the Merger, were received in the Merger and represent the conversion of an equal number of Medtronic common stock shares for $62.76 per share. The New Medtronic stock option has the same terms and conditions as the original Medtronic stock option. These options became exercisable in four equal annual installments beginning on July 28, 2015, which was the first anniversary of the grant. Read SEC document |
| August 31, 2018 Filed Sep 5, 2018 16:33 UTC | Medtronic plc MDT · Entity 2888 | SaleOrdinary Shares | 26,159 | $96.29 | $2,518,797.79 |
DisclosureSEC source: 0001127602-18-026803 · form4.xml · nonDerivative · entry 4 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,647 F1 · kind: The exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $96.04 to $96.44, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 31, 2018 Filed Sep 5, 2018 16:33 UTC | Medtronic plc MDT · Entity 2888 | Exercise / conversionOrdinary Shares | 18,324 | $62.76 | $1,150,014.24 |
DisclosureSEC source: 0001127602-18-026803 · form4.xml · nonDerivative · entry 3 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,806 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 31, 2018 Filed Sep 5, 2018 16:33 UTC | Medtronic plc MDT · Entity 2888 | Exercise / conversionOrdinary Shares | 7,436 | $62.76 | $466,683.36 |
DisclosureSEC source: 0001127602-18-026803 · form4.xml · nonDerivative · entry 2 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,482 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 31, 2018 Filed Sep 5, 2018 16:33 UTC | Medtronic plc MDT · Entity 2888 | Exercise / conversionOrdinary Shares | 399 | $62.76 | $25,041.24 |
DisclosureSEC source: 0001127602-18-026803 · form4.xml · nonDerivative · entry 1 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,046 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 03, 2018 Filed Aug 7, 2018 16:30 UTC | Medtronic plc MDT · Entity 2888 | Tax withholdingOrdinary Shares | 4,822 | $90.48 | $436,294.56 |
DisclosureSEC source: 0001127602-18-024844 · form4.xml · nonDerivative · entry 1 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,647 Read SEC document |
| July 30, 2018 Filed Aug 1, 2018 15:47 UTC | Medtronic plc MDT · Entity 2888 | GrantStock Option (Right to Buy) · Derivative | 1,695 | $0.00 Strike: $89.08 | $0.00 |
DisclosureSEC source: 0001127602-18-024239 · form4.xml · derivative · entry 3 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,695 Underlying: Ordinary Shares · 1,695 shares Expires 2028-07-30 F2 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 30, 2018 Filed Aug 1, 2018 15:47 UTC | Medtronic plc MDT · Entity 2888 | GrantStock Option (Right to Buy) · Derivative | 56,485 | $0.00 Strike: $89.08 | $0.00 |
DisclosureSEC source: 0001127602-18-024239 · form4.xml · derivative · entry 2 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,485 Underlying: Ordinary Shares · 56,485 shares Expires 2028-07-30 F2 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 30, 2018 Filed Aug 1, 2018 15:47 UTC | Medtronic plc MDT · Entity 2888 | GrantOrdinary Shares | 9,355 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-024239 · form4.xml · nonDerivative · entry 1 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,472 F1 · kind: The restrictions on these restricted stock units shall lapse 100% on the third anniversary of the Grant Date if the Company's cumulative non-GAAP diluted earnings per share ("EPS") growth during the 36-month period ending on the last day of the Company's fiscal year 2021 equals or exceeds a 3% cumulative compound annual growth rate, as determined by the Compensation Committee. Read SEC document |
| July 28, 2018 Filed Jul 31, 2018 15:17 UTC | Medtronic plc MDT · Entity 2888 | Tax withholdingOrdinary Shares | 10,038 | $88.66 | $889,969.08 |
DisclosureSEC source: 0001127602-18-024106 · form4.xml · nonDerivative · entry 1 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,117 F1 · balance_after: This balance increased by 1,327 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| July 28, 2018 Filed Aug 2, 2018 17:22 UTC Amendment | Medtronic plc MDT · Entity 2888 | Tax withholdingOrdinary Shares | 9,042 | $88.66 | $801,663.72 |
DisclosureSEC source: 0001127602-18-024486 · form4a.xml · nonDerivative · entry 1 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,113 F1 · shares: Too many tax shares were initially withheld in error. This has been corrected from 10038 to 9042. Read SEC document |
| January 05, 2018 Filed Jan 8, 2018 17:07 UTC | Medtronic plc MDT · Entity 2888 | Exercise / conversionStock Option (Right to Buy) · Derivative | 26,158 | $0.00 Strike: $62.76 | $0.00 |
DisclosureSEC source: 0001127602-18-001398 · form4.xml · derivative · entry 3 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,159 Underlying: Ordinary Shares · 26,158 shares Expires 2024-07-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option to purchase 1,594 ordinary shares of New Medtronic for $62.76 per share, which was unvested at the effective time of the Merger, was received in the Merger and represents the conversion of 1,594 Medtronic common stock shares for $62.76 per share. This New Medtronic stock option has the same terms and conditions as the original Medtronic stock option. F4 · derivative.exercise_date: This option to purchase 29,743 New Medtronic ordinary shares for $62.76 per share, which was unvested at the effective time of the Merger, was received in the Merger and represents the conversion of 29,743 Medtronic common stock shares for $62.76 per share. This New Medtronic stock option has the same terms and conditions as the original Medtronic stock option. F5 · derivative.exercise_date: This option to purchase 73,296 New Medtronic ordinary shares for $62.76 per share, which was unvested at the effective time of the Merger, was received in the Merger and represents the conversion of 73,296 Medtronic common stock shares for $62.76 per share. This New Medtronic stock option has the same terms and conditions as the original Medtronic stock option. Read SEC document |
| January 05, 2018 Filed Jan 8, 2018 17:07 UTC | Medtronic plc MDT · Entity 2888 | SaleOrdinary Shares | 26,158 | $85.00 | $2,223,430.00 |
DisclosureSEC source: 0001127602-18-001398 · form4.xml · nonDerivative · entry 2 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,828 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 05, 2018 Filed Jan 8, 2018 17:07 UTC | Medtronic plc MDT · Entity 2888 | Exercise / conversionOrdinary Shares | 26,158 | $62.76 | $1,641,676.08 |
DisclosureSEC source: 0001127602-18-001398 · form4.xml · nonDerivative · entry 1 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,986 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This balance increased by 356 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.